Safety Evaluation for Infant RSV Antibody Treatments Initiated by FDA

Post by : Bianca Suleiman

The U.S. Food and Drug Administration has initiated a safety evaluation of two injectable medications aimed at shielding infants and toddlers from respiratory syncytial virus (RSV), a prevalent but potentially serious virus that results in numerous hospital admissions for young children annually.

The long-acting antibody treatments manufactured by Merck and Sanofi, while not vaccines, provide critical protection for infants and toddlers against RSV. Officials noted that this review is part of a routine assessment to ensure these drugs remain safe for public use.

Typically presenting cold-like symptoms in healthy individuals, RSV can cause severe respiratory challenges in infants, young children, and older adults. Although the FDA has authorized vaccines for older people and pregnant women, these antibody treatments are still the primary preventive measure for infants.

Merck’s Enflonsia injection is administered before or during a child's first RSV season, which lasts about five months, while Sanofi’s Beyfortus has reached over six million children globally. Both firms have indicated no new safety issues from clinical trials or post-market observations.

The CDC had previously advised administering antibody shots to infants born right before or during RSV season, particularly if their mothers hadn’t received a late-pregnancy vaccine. This guidance also extends to specific high-risk children aged 8 to 19 months.

This safety review occurs amid heightened scrutiny of vaccine and drug safety under Health Secretary Robert F. Kennedy Jr., who has replaced all CDC advisory committee members and is currently pushing to reduce routine newborn vaccinations for hepatitis B.

FDA representatives clarified that the ongoing review does not indicate any established safety concerns. Depending on the outcomes of current data evaluations, product labeling may be revised.